[Memantine for optic nerve atrophy in Friedreich's Ataxia]

Area of Science:

• Neuro-ophthalmology
• Neurodegenerative Diseases
• Pharmacology

Background:

• Friedreich's ataxia (FA) is a rare inherited disorder.
• Optic nerve atrophy leading to visual loss is a common complication in FA.
• Current treatment options for optic nerve atrophy in FA are limited.

Observation:

• A 24-year-old patient with FA presented with significant visual impairment due to optic nerve atrophy.
• The patient received off-label treatment with memantine, an N-methyl-D-aspartate (NMDA) receptor antagonist.
• Treatment was initiated after interdisciplinary consultation and informed consent.

Findings:

• A 1-year follow-up using optical coherence tomography (OCT) revealed no further loss of the nerve fiber layer.
• The patient's visual acuity remained stable throughout the follow-up period.
• This suggests a potential neuroprotective effect of memantine in this context.

Implications:

• Memantine may be a viable therapeutic option for managing acute optic nerve atrophy in Friedreich's ataxia.
• Further research, including larger studies, is warranted to confirm these preliminary findings.
• This case highlights the importance of considering novel therapeutic strategies for rare neurodegenerative conditions.